​

Castle Biosciences Ownership | Who Owns Castle Biosciences?

OverviewForecastRevenueFinancialsChartTranscripts

Castle Biosciences Ownership Summary

Castle Biosciences is owned by 92.27% institutional investors, 2.56% insiders, and 5.17% retail investors. Blackrock is the largest institutional shareholder, holding 11.08% of CSTL shares. Bellevue Healthcare Ord is the top mutual fund, with 4.32% of its assets in Castle Biosciences shares.

CSTL Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockCastle Biosciences92.27%2.56%5.17%
SectorHealthcare Stocks 50.44%12.38%37.18%
IndustryDiagnostics & Research Stocks77.65%9.11%13.24%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock3.04M11.08%$66.29M
Blackrock funding, inc. /de3.29M11.01%$78.51M
Rtw investments, lp2.78M9.30%$66.26M
Vanguard group2.20M8.78%$85.57M
Principal financial group1.73M5.78%$41.18M
Vanguard capital management1.23M4.10%$29.25M
Acadian asset management918.67K3.07%$21.90M
Summit partners public asset management824.87K2.76%$19.67M
State street822.08K2.75%$19.63M
Allianz asset management gmbh811.32K2.71%$19.92M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Aigh capital management545.10K0.82%$13.00M
Rtw investments, lp2.78M0.57%$66.26M
Formula growth46.00K0.51%$1.13M
Parkman healthcare partners144.79K0.35%$3.45M
Summit partners public asset management824.87K0.35%$19.67M
Portolan capital management328.82K0.29%$7.84M
Perkins capital management16.14K0.29%$384.94K
Palisade capital management, lp231.93K0.24%$5.53M
Green alpha advisors9.94K0.16%$237.09K
Alpha dna investment management15.17K0.15%$404.39K

Top Buyers

HolderShares% AssetsChange
Mackenzie financial793.51K0.02%719.40K
Blackrock3.04M0.00%449.29K
Acadian asset management918.67K0.03%434.23K
Point72 asset management357.32K0.01%357.32K
Kennedy capital management348.37K0.15%348.37K

Top Sellers

HolderShares% AssetsChange
Portolan capital management328.82K0.29%-1.02M
Park west asset management---556.49K
Eventide asset management---386.43K
Palisade capital management, lp231.93K0.24%-303.95K
Bellevue group---301.10K

New Positions

HolderShares% AssetsChangeValue
Kennedy capital management348.37K0.15%348.37K$8.31M
Sixth street partners management company254.53K0.00%254.53K$6.07M
First trust advisors lp145.06K0.00%145.06K$3.46M
Norges bank60.10K0.00%60.10K$1.43M
Formula growth46.00K0.51%46.00K$1.13M

Sold Out

HolderChange
Larson financial group-1.00
Nelson, van denburg & campbell wealth management group-1.00
Twin peaks wealth advisors-1.00
Stephens consulting-2.00
Wealth preservation advisors-4.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 2026178-6.32%27,578,698-0.11%921.08%1053.96%56-8.20%
Mar 31, 2026188-4.57%27,601,5221.07%940.79%101-3.81%59-16.90%
Dec 31, 2025157-10.80%19,552,468-26.63%780.92%80-18.37%575.56%
Sep 30, 202517112.50%26,525,363-0.04%911.09%939.41%5420.00%
Jun 30, 2025151-17.03%26,530,4542.55%911.12%85-19.81%44-18.52%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Bellevue Healthcare Ord1.20M4.32%1.20M
Vanguard US Total Market Shares ETF829.40K2.96%-
Vanguard Total Stock Mkt Idx Inv852.70K2.81%-
Vanguard Morn Total Stk Mkt Idx Investor852.70K2.79%-
iShares Russell 2000 ETF764.45K2.50%-13.54K
Strategic Advisers U.S. Total Stock{mg}693.06K2.47%-
Wasatch Small Cap Growth Investor675.19K2.41%-14.34K
Principal SmallCap R5729.94K2.41%32.10K
Principal U.S. Small Cap Equity729.94K2.41%-23.70K
Principal U.S. Small Cap Select Equity729.94K2.41%-23.70K

Recent Insider Transactions

DateNameRoleActivityValue
Aug 17, 2026Juvenal Tobin W Chief Commercial OfficerSell$51.19K
Aug 14, 2026Stokes Frank Chief Financial OfficerSell$741.51K
Aug 14, 2026MAETZOLD DEREK J Pres. & Chief Exec. OfficerSell$69.23K
Aug 14, 2026MAETZOLD DEREK J Pres. & Chief Exec. OfficerSell$33.02K
Aug 14, 2026MAETZOLD DEREK J Pres. & Chief Exec. OfficerSell$81.47K

Insider Transactions Trends

DateBuySell
2026 Q3-46
2026 Q2-29
2026 Q1-26
2025 Q4-26
2025 Q3-7

CSTL Ownership FAQ

Who Owns Castle Biosciences?

Castle Biosciences shareholders are primarily institutional investors at 92.27%, followed by 2.56% insiders and 5.17% retail investors. The average institutional ownership in Castle Biosciences's industry, Diagnostics & Research Stocks, is 77.65%, which Castle Biosciences exceeds.

Who owns the most shares of Castle Biosciences?

Castle Biosciences’s largest shareholders are Blackrock (3.04M shares, 11.08%), Blackrock funding, inc. /de (3.29M shares, 11.01%), and Rtw investments, lp (2.78M shares, 9.30%). Together, they hold 31.39% of Castle Biosciences’s total shares outstanding.

Does Blackrock own Castle Biosciences?

Yes, BlackRock owns 11.08% of Castle Biosciences, totaling 3.04M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 66.29M$. In the last quarter, BlackRock increased its holdings by 449.29K shares, a 17.31% change.

Who is Castle Biosciences’s biggest shareholder by percentage of total assets invested?

Aigh capital management is Castle Biosciences’s biggest shareholder by percentage of total assets invested, with 0.82% of its assets in 545.1K Castle Biosciences shares, valued at 13M$.

Who is the top mutual fund holder of Castle Biosciences shares?

Bellevue Healthcare Ord is the top mutual fund holder of Castle Biosciences shares, with 4.32% of its total shares outstanding invested in 1.2M Castle Biosciences shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools